Haleon (LON:HLN) Hits New 1-Year High – Should You Buy?

Haleon plc (LON:HLN)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 431.82 ($5.61) and last traded at GBX 394.10 ($5.12), with a volume of 65438391 shares changing hands. The stock had previously closed at GBX 388.20 ($5.04).

Wall Street Analyst Weigh In

Separately, Berenberg Bank lifted their price objective on Haleon from GBX 456 ($5.92) to GBX 457 ($5.93) and gave the stock a “buy” rating in a report on Friday, February 28th.

Haleon Stock Up 1.4 %

The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The company has a market cap of £35.52 billion, a PE ratio of 33.10, a PEG ratio of 1.49 and a beta of 0.19. The company’s fifty day moving average is GBX 388.17 and its 200-day moving average is GBX 381.73.

Haleon (LON:HLN) last released its quarterly earnings results on Friday, February 28th. The company reported GBX 15.80 ($0.21) EPS for the quarter. Haleon had a net margin of 9.66% and a return on equity of 6.54%. On average, analysts predict that Haleon plc will post 19.5033282 EPS for the current year.

Haleon Increases Dividend

The business also recently disclosed a dividend, which will be paid on Thursday, June 5th. Stockholders of record on Thursday, April 24th will be paid a GBX 4.60 ($0.06) dividend. The ex-dividend date is Thursday, April 24th. This represents a dividend yield of 1.18%. This is an increase from Haleon’s previous dividend of $2.00. Haleon’s dividend payout ratio (DPR) is 50.46%.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.